The calcium channel inhibitor lacidipine inhibits Zika virus replication in neural progenitor cells.
Antiviral drugs
Cholesterol transport
Dengue virus
Lacidipine
Zika virus
Journal
Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
24
12
2021
revised:
21
03
2022
accepted:
27
03
2022
pubmed:
4
4
2022
medline:
18
5
2022
entrez:
3
4
2022
Statut:
ppublish
Résumé
After decades of being considered non-pathogenic, Zika virus (ZIKV) emerged as an important threat to human health during the epidemic of 2015-2016. ZIKV infections are usually asymptomatic, but can cause Guillain-Barré syndrome in adults and microcephaly in newborns. As there are currently no approved antiviral drugs against ZIKV, we tested anti-ZIKV activity of compounds from the NIH Clinical Collection for which we previously showed antiviral activity against the related dengue virus. One of the top hits from the screen was lacidipine, a 1,4-dihydropyridine calcium antagonist that is approved as an antihypertensive drug. Our data show that lacidipine is antiviral against ZIKV (strain H/PF/2013) in both Vero cells and induced pluripotent stem cell (iPSC)-derived human neural progenitor cells with IC
Identifiants
pubmed: 35367280
pii: S0166-3542(22)00082-1
doi: 10.1016/j.antiviral.2022.105313
pii:
doi:
Substances chimiques
Antiviral Agents
0
Calcium Channel Blockers
0
Calcium Channels
0
Dihydropyridines
0
Lipids
0
lacidipine
260080034N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105313Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.